VIRGINIA RETIREMENT SYSTEMS ET Al Invests $3.33 Million in Indivior PLC $INDV

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Indivior PLC (NASDAQ:INDV) in the second quarter, Holdings Channel reports. The firm bought 81,200 shares of the company’s stock, valued at approximately $3,332,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. California State Teachers Retirement System acquired a new position in Indivior during the 2nd quarter worth $201,163,000. AlphaGrep UK Ltd acquired a new stake in shares of Indivior in the 2nd quarter valued at $259,000. Valued Retirements Inc. acquired a new position in shares of Indivior during the second quarter worth $300,000. denkapparat Operations GmbH purchased a new position in Indivior in the second quarter valued at $454,000. Finally, TD Waterhouse Canada Inc. acquired a new stake in Indivior in the second quarter valued at $63,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Insider Activity at Indivior

In related news, CAO Woodrow D. Anderson purchased 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The stock was purchased at an average cost of $35.69 per share, with a total value of $53,535.00. Following the completion of the acquisition, the chief accounting officer directly owned 27,638 shares in the company, valued at $986,400.22. This trade represents a 5.74% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Christian Heidbreder sold 18,586 shares of the business’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $41.14, for a total transaction of $764,628.04. Following the completion of the transaction, the insider directly owned 209,337 shares in the company, valued at $8,612,124.18. This represents a 8.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is owned by corporate insiders.

Indivior Stock Performance

Shares of NASDAQ:INDV opened at $34.77 on Thursday. Indivior PLC has a one year low of $22.22 and a one year high of $42.81. The stock has a market capitalization of $4.10 billion, a price-to-earnings ratio of 12.46 and a beta of 0.82. The company has a 50-day simple moving average of $38.39 and a 200-day simple moving average of $36.04.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. The firm had revenue of $343.00 million for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. As a group, research analysts forecast that Indivior PLC will post 3.66 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Zacks Research lowered Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Weiss Ratings upgraded shares of Indivior from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, September 4th. Craig Hallum restated a “buy” rating and issued a $53.00 target price on shares of Indivior in a report on Tuesday, August 4th. Finally, Barclays dropped their target price on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Indivior currently has an average rating of “Moderate Buy” and a consensus price target of $45.17.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.